Effect of Optic Edge Design in a Silicone Intraocular Lens on Posterior Capsule Opacification
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00428363 |
Recruitment Status :
Completed
First Posted : January 30, 2007
Last Update Posted : January 30, 2007
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Purpose: To compare the posterior capsule opacification (PCO) inhibiting effect of the sharp posterior optic edge design of the Clariflex silicone intraocular lens (IOL) with that of the double-round edge design of the SI40 (Phacoflex) silicone IOL over a period of 3 years.
Setting: Department of Ophthalmology, Medical University of Vienna, Vienna, Austria.
Methods: Fifty-two patients with bilateral age-related cataract (104 eyes) were included in this randomized, prospective, bilateral, patient- and examiner-masked clinical trial with intra-individual comparison. Each study patient had cataract surgery in both eyes and received an SI40 IOL (anterior and posterior round optic edges) in one eye and a Clariflex IOL with OptiEdge (round anterior and sharp posterior optic edge) in the other eye. Follow-up examinations were at one week, one month, six months, one, two, and three years. Digital retroillumination images were taken of each eye. The amount of PCO was assessed subjectively at the slit-lamp and objectively using automated image analysis software (AQUA) one, two, and three years after surgery.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Cataract Pseudophakia | Device: Cataract surgery with implantation of an intraocular lens | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Enrollment : | 52 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double |
Primary Purpose: | Prevention |
Study Start Date : | June 2001 |
Study Completion Date : | March 2006 |
- amount of posterior capsule opacification (objective and subjective score 0-10)
- visual acuity

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 40 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- bilateral, age related cataract
Exclusion Criteria:
- history of other ocular disease or intraocular surgery
- diabetes requiring medical control

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00428363
Austria | |
Dept. of Ophthalmology, Medical University of Vienna | |
Vienna, Austria, 1090 |
Principal Investigator: | Rupert Menapace, MD | Medical University of Vienna | |
Principal Investigator: | Oliver Findl, MD | Medical University of Vienna |
Publications of Results:
Other Publications:
ClinicalTrials.gov Identifier: | NCT00428363 |
Other Study ID Numbers: |
EK2512001 |
First Posted: | January 30, 2007 Key Record Dates |
Last Update Posted: | January 30, 2007 |
Last Verified: | January 2007 |
posterior capsule opacification PCO after cataract |
intraocular lens optic edge design sharp optic edge |
Cataract Capsule Opacification Pseudophakia Lens Diseases Eye Diseases |